Developing an antibody drug encapsulation nanoagent targeting HER2 for cancer treatment.

J Transl Med · 2026 · PMC12874675 · PMID 41508040

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

a decreasing trendp > 0.05actually significant

Though the tumor volume (TV) exhibited a decreasing trend in the Tr-ACT2 group compared to the irinotecan group on day 14, the difference was not statistically significant ( p > 0.05), likely due to the limited sample size.

also in 44,411 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.